Rebecca Richards
page-template,page-template-full_width,page-template-full_width-php,page,page-id-1229,bridge-core-3.1.2,,vertical_menu_enabled,qode-title-hidden,qode_grid_1300,side_area_uncovered_from_content,qode-theme-ver-30.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.9.0,vc_responsive

Rebecca Richards, MD, PhD


Assistant Professor, Department of Pediatrics
Division of Pediatric Hematology, Oncology, and Bone Marrow Transplantation


The Richards lab focuses on developing chimeric antigen receptor T (CAR-T) cell therapy for acute myeloid leukemia (AML), a disease that can be difficult to treat and is associated with many treatment-related toxicities. CAR-T cell therapy has revolutionized treatment for patients with B cell malignancies, and is an attractive option for treatment of AML. Despite promising pre-clinical data, translation to patients has been hampered by tumor heterogeneity and the possibility of on-target, off-tumor toxicity to healthy tissues. The Richards lab will engineer next-generation CAR-T cells with improved tumor specificity and will use pre-clinical models to identify critical components of AML tumor cell and CAR-T cell biology that will inform further clinical development.